Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02256267 · ClinicalTrials.gov registry record · Phase 1
A Study of LY2835219 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02256267 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 24 participants.
The verdict
NCT02256267, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The aim of this two-period study is to compare how much of the study drug gets into the blood stream when it is given as a single oral dose and when it is given as a single oral dose in combination with rifampin (a Food and Drug Administration \[FDA\] approved antibiotic that is used to treat tuberculosis, a bacterial infection that mainly affects the lungs, and other infections). Each participant will complete both study periods. The study will last about 34 days. Screening is required within 28 days before study drug is given.
Interventions
- DRUG Rifampin
- DRUG LY2835219
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2014-10 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02256267
The ClinicalTrials.gov registry entry for NCT02256267 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rifampin is the first listed.
NCT02256267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02256267 about?
NCT02256267 is a clinical study titled "A Study of LY2835219 in Healthy Participants". The aim of this two-period study is to compare how much of the study drug gets into the blood stream when it is given as a single oral dose and when it is given as a single oral dose in combination with rifampin (a Food and Drug Administration \[FDA\] approved antibiotic that is used to treat tuberc...
What is the current status of trial NCT02256267?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2014-10. Estimated completion is 2014-11.
What interventions are being tested in trial NCT02256267?
The interventions under investigation include: Rifampin (DRUG), LY2835219 (DRUG).
Who is sponsoring clinical trial NCT02256267?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.